ClinicalTrials.gg
CompletedNCT07219550Updated Aug 4, 2026

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

A Phase 1 interventional study of Calderasib in Healthy and Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to participants with hepatic (liver) impairment and healthy participants. Researchers also want to learn about the safety of MK-1084 when it is given to people with hepatic impairment and if people with hepatic impairment can tolerate it.

02

Conditions studied

  • Healthy
  • Hepatic Impairment
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The main inclusion criteria include but are not limited to:

All participants:

  • Has a (BMI) between 18.0 and 42.0 kg/m\^2

Participants with hepatic impairment (HI):

  • Has a diagnosis of chronic, stable hepatic insufficiency at screening with features of cirrhosis

Healthy volunteers:

  • Is medically healthy with no medical history

The main exclusion criteria include but are not limited to:

All participants:

  • Has a history of gastrointestinal disease which may affect food and drug absorption
  • Has a history of cancer ()
  • Has a positive result for (HIV)
  • Has had major surgery and/or donated or lost significant volume of blood within 56 days prior to dosing

Participants with HI:

  • Has had severe complications of liver disease within the preceding 3 months of screening
  • Has a history of recent (within 3 months prior to screening) variceal bleeds
  • Has evidence of hepatorenal syndrome
  • Is not in sufficient health, with regard to stability of HI, to undergo participation in the study with anticipated survival of \< 3 months
  • Has a history of liver or other solid organ transplantation
  • Has an active infection requiring systemic therapy
  • Requires paracentesis more often than 2 times per month
  • Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting
  • Has received antiviral and/or immune modulating therapy for virus (HBV) or virus (HCV) within 90 days prior to dosing
  • Is using HIV protease inhibitors
  • Is positive for Hepatitis B surface antigen (HBsAg)
  • Is positive for HCV

Healthy volunteers:

  • Has positive results for HBsAg or HCV
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Calderasib

    All participants will receive a single oral dose of calderasib on Day 1.

    Drug: Calderasib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve from 0 to the Time of the Last Quantifiable Sample (AUC0-last) of Calderasib

    Blood samples will be collected to determine the AUC0-last of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  2. Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC0-inf) of Calderasib

    Blood samples will be collected to determine the AUC0-inf of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  3. Area Under the Concentration Versus Time Curve from 0 to 24 hours post-dose (AUC0-24) of Calderasib

    Blood samples will be collected to determine the AUC0-24 of calderasib in plasma.

    Time frame: Up to approximately 24 hours post-dose

  4. Maximum Observed Drug Concentration (Cmax) of Calderasib

    Blood samples will be collected to determine the Cmax of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  5. Time to Maximum Observed Drug Concentration (Tmax) of Calderasib

    Blood samples will be collected to determine the Tmax of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  6. Apparent Terminal Half-life (t1/2) of Calderasib

    Blood samples will be collected to determine the t1/2 of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  7. Apparent Clearance (CL/F) of Calderasib

    Blood samples will be collected to determine the CL/F of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

  8. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Calderasib

    Blood samples will be collected to determine the Vz/F of calderasib in plasma.

    Time frame: At designated timepoints up to approximately 7 days post-dose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants experiencing AEs will be reported.

    Time frame: Up to approximately 14 days

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The number of participants discontinuing the study due to AEs will be reported.

    Time frame: Up to approximately 14 days

07

Study locations

3 sites
  • Arizona Clinical Trials ( Site 0003)
    Chandler, Arizona 85225, United States
  • Orlando Clinical Research Center ( Site 0001)
    Orlando, Florida 32809, United States
  • The Texas Liver Institute ( Site 0002)
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jul 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 22, 2025
StartActual
Nov 5, 2025
Primary completionActual
Jul 15, 2026
CompletionActual
Jul 15, 2026
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219550
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Nov 5, 2025
Primary completion
Jul 15, 2026
Completion
Jul 15, 2026
Last update
Aug 4, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calderasib

Start the discussion